FindTrial
Sign In

Effects of using hydroxychloroquine and azithromycin in the treatment of confirmed COVID-19 positive patients

USAGE OF HYDROXYCHLOROQUINE AND AZITHROMYCIN IN INDICATED CONFIRMED COVID-19 POSITIVE CASES FOR ITS EFFICACY IN EARLY NEGATIVE CONVERSION- PILOT OBSERVATIONAL STUDY AIIMS RAIPUR.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/05/024982
Enrollment
50
Registered
2020-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i) All age group (special: children, all preganant women); ii) PCR documented SARS-CoV-2 carriage in nasopharyngeal sample at admission whatever their clinical status.

Exclusion criteria

Exclusion criteria: • Non consented. • Patients will be excluded if they have a known allergy to hydroxychloroquine /chloroquine and/ or Azithromycin and have any other contraindication to treatment with the study drug(Chloroquine or Azithromycin) including retinopathy, G6PD deficiency and QT prolongation. • Lactating mothers will be excluded based on their declaration.

Design outcomes

Primary

MeasureTime frame
virological clearanceTimepoint: day-6 post-inclusion—

Secondary

MeasureTime frame
virological clearance overtime during the study period, clinical follow-up (body temperature, respiratory rate, duration of stay at hospital and mortality), and occurrence of side effects.Timepoint: 28 days—

Countries

India

Contacts

Public ContactDr PUGAZHENTHAN T

ALL INDIA INSTITUTE OF MEDICAL SCIENCES AIIMS RAIPUR

drpugal23@gmail.com9486279090

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026